Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Kato ET, et al. Among authors: raz i. Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18. Circulation. 2019. PMID: 30882238 Clinical Trial.
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Berl T, et al. Among authors: raz i. Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010. Ann Intern Med. 2003. PMID: 12667024 Clinical Trial.
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O, Raz I, Scirica BM, Hirshberg B, Stahre CI, Steg PG, Davidson J, Ohman P, Price DL, Frederich B, Udell JA, Braunwald E, Bhatt DL. Mosenzon O, et al. Among authors: raz i. Diabetes Metab Res Rev. 2013 Jul;29(5):417-26. doi: 10.1002/dmrr.2413. Epub 2013 May 21. Diabetes Metab Res Rev. 2013. PMID: 23564755 Clinical Trial.
Emerging gliptins for type 2 diabetes.
Cahn A, Raz I. Cahn A, et al. Among authors: raz i. Expert Opin Emerg Drugs. 2013 Jun;18(2):245-58. doi: 10.1517/14728214.2013.807796. Expert Opin Emerg Drugs. 2013. PMID: 23725569 Review.
Early insulinization to prevent diabetes progression.
Raz I, Mosenzon O. Raz I, et al. Diabetes Care. 2013 Aug;36 Suppl 2(Suppl 2):S190-7. doi: 10.2337/dcS13-2014. Diabetes Care. 2013. PMID: 23882045 Free PMC article. Review. No abstract available.
472 results